Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Piper Sandler Upgrades Solid Biosciences to Overweight, Raises Price Target to $20

Author: Benzinga Newsdesk | March 14, 2024 04:57am
Piper Sandler analyst Christopher Raymond upgrades Solid Biosciences (NASDAQ:SLDB) from Neutral to Overweight and raises the price target from $8 to $20.

Posted In: SLDB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist